XL 1p36/1q25 del
XL 1p36/1q25 del detects deletions in the short arm of chromosome 1. The orange labeled probe hybridizes to the CHD5 locus at 1p36. A green labeled probe hybridizes to the ABL2 locus at 1q25 and functions as a reference probe.
This probe is intended for methanol/acetic-acid fixed cells and tissue sections.
The 2016 ´World Health Organization Classification of Tumors of the Central Nervous System´(WHO 2016) combines, for the first time, histological features and molecular signatures for the definition of many tumor entities. Gliomas are a category of tumors of the brain and spinal cord starting in glia cells. Oligodendrogliomas are a subtype of gliomas accounting for up to 18% of all cases. According to the WHO 2016, the classification of an oligodendroglioma requires information about the isocitrate dehydrogenase mutation status and 1p/19q loss of heterozygosity (LOH). LOH of 1p can be detected in about 67% of oligodendroglial tumors and has also been identified in neuroblastomas and other tumor entities. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion, generally have a good prognosis. Co-deletion of 1p/19q has also predictive character, the molecular status of 1p/19q is relevant for therapy decisions.
Cena za kus: pro registrované
This probe is intended for methanol/acetic-acid fixed cells and tissue sections.
The 2016 ´World Health Organization Classification of Tumors of the Central Nervous System´(WHO 2016) combines, for the first time, histological features and molecular signatures for the definition of many tumor entities. Gliomas are a category of tumors of the brain and spinal cord starting in glia cells. Oligodendrogliomas are a subtype of gliomas accounting for up to 18% of all cases. According to the WHO 2016, the classification of an oligodendroglioma requires information about the isocitrate dehydrogenase mutation status and 1p/19q loss of heterozygosity (LOH). LOH of 1p can be detected in about 67% of oligodendroglial tumors and has also been identified in neuroblastomas and other tumor entities. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion, generally have a good prognosis. Co-deletion of 1p/19q has also predictive character, the molecular status of 1p/19q is relevant for therapy decisions.
Cena za kus: pro registrované
